Clinical Trials Browser

OTHER × atezolizumab × Gynecologic × Clear all

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05542407 2026-01-29

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Phase 1 Recruiting

GynecologicOtherSarcoma

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

NCT05092373 2026-01-14

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Endometrial Neoplasms

NCT03614949 2025-12-19

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03526432 2025-10-24

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT04486352 2025-09-04

EndoMAP

Phase 1/2 Recruiting

Endometrial Neoplasms

NCT03612791 2025-06-03

ATEZOLACC

Phase 2 Completed

Locally Advanced Cervical Cancer

NCT03694262 2025-05-30

EndoBARR

Phase 2 Active not recruiting

30 enrolled 7 charts

Endometrial Neoplasms

NCT03603184 2025-05-09

AtTEnd

Phase 3 Completed

Neoplasms, Endometrial Neoplasms

NCT02891824 2025-02-11

ATALANTE

Phase 3 Completed

Ovarian Neoplasms

NCT03946358 2024-12-20

VolATIL

Phase 2 Completed

GastrointestinalGynecologicHead & Neck

Anal Canal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms

NCT03598270 2024-08-30

ANITA

Phase 3 Completed

Ovarian Neoplasms

NCT03340376 2024-07-03

Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT03363867 2023-08-07

BEACON

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03394885 2021-08-12

AdORN

Phase 1/2 Completed

18 enrolled 15 charts

Ovarian Neoplasms